Phreesia Inc Director Sells 465 Shares of the Company

Phreesia Inc Director Lisa Egbuonu-davis sold 465 shares of the company on July 15, 2025, for $27.64 apiece, bringing the total number of shares owned to 21,572. The healthcare technology company provides a patient intake management platform that automates the intake process to improve efficiency and patient experience. Despite the recent sale, the stock is considered modestly undervalued based on its GuruFocus Value.

Phreesia Inc, a healthcare technology company, saw its Director Lisa Egbuonu-Davis sell 465 shares of the company on July 15, 2025, at a price of $27.64 per share, totaling $12,852 [2]. This transaction, executed under a Rule 10b5-1 trading plan adopted on September 24, 2024, left Egbuonu-Davis with 21,572 shares directly owned [2].

Phreesia provides a patient intake management platform that automates the intake process to improve efficiency and patient experience. Despite the recent sale, the stock remains modestly undervalued based on its GuruFocus Value [2]. The company is valued at $1.55 billion and has seen its stock decline nearly 10% over the past week [2].

Phreesia reported its first-quarter earnings, showing strong financial performance that exceeded consensus estimates for both revenue and adjusted EBITDA. The company achieved a 16% growth rate in its Subscription and services segment, boosted by approximately $1 million in non-recurring revenue [2]. Despite some challenges in the Network Solutions segment, Phreesia maintained a robust profitability trajectory, with adjusted EBITDA soaring by 408% to $20.8 million, surpassing estimates by about 30% [2].

Analysts have responded to Phreesia’s financial results with varied perspectives. Piper Sandler maintained an Overweight rating with a $33 target, citing Phreesia’s solid quarterly results and increased guidance for fiscal year 2026 [2]. Meanwhile, Canaccord Genuity adjusted its price target to $34 from $35 but kept a Buy rating, acknowledging the company’s continued growth and profitability [2]. DA Davidson also reiterated a Buy rating with a $34 target, highlighting Phreesia’s balance between profit growth and certain challenges [2]. Raymond James maintained an Outperform rating with a $30 target, emphasizing the company’s strong margins and strategic investments [2]. JPMorgan expressed optimism about Phreesia’s growth prospects, reiterating an overweight rating due to the company’s revenue diversification strategy and recent profitability improvements [2].

References:
[1] https://www.tradingview.com/news/tradingview:4f6ddcc39c3e0:0-phreesia-executives-conduct-stock-transactions/
[2] https://www.investing.com/news/insider-trading-news/phreesia-director-egbuonudavis-sells-12852-in-stock-93CH-4140881